▶ The PolicyIQ framework · v2 (six channels) click to expand — this signal: trade & market access (primary), institutional & political risk (secondary)

PolicyIQ treats policy as a measurable signal stream organized into a three-level architecture. L3 is the per-signal deep-dive — it answers "how do I trade this specific signal" via transmission chain, scenario probability grid, and concrete trade expressions. For Section 232 100% pharma, the L3 build is unusual because the alpha is in the implementation details, not the headline rate. The 100% number is in consensus; the phasing, country carve-outs, reshoring credit mechanism, and definition of "final product" are not. This L3 makes the implementation variables the analytical centerpiece.

Signal classification

Primary channel: Trade & market access (Section 232 is the canonical trade-channel signal). Secondary channel: Institutional & political risk (the discretionary nature of Section 232 implementation makes it sensitive to executive-branch posture and to potential SCOTUS review on commerce clause grounds, similar to the IEEPA regression). Maturity: Imminent — announced Q1 2026, implementation framework expected Q2–Q3 2026. Velocity: Accelerating — the gap between announcement and implementation is shorter than for prior Section 232 actions.

Why this signal warrants L3 treatment

Three criteria from the framework: (1) it is the dominant single signal in a HIGH-materiality industry, (2) the implementation timing creates a specific window where directional positioning is possible, and (3) the firm-attribute exposure is differentiated enough that the trade is pair-style rather than directional. All three are satisfied. The L3 build is also a stress test of the framework's claim that implementation-detail variability is where the framework finds alpha that single-signal sell-side analyses miss.

L3 signal deep-dive · Section 232 100% pharma tariff · April 2026

The headline rate is in consensus. The implementation details are not. That is where the alpha sits.

Section 232 100% on patented pharmaceutical imports was announced Q1 2026 and is the dominant active signal in pharma. The 100% headline rate is universally modeled by sell-side and is reflected in current sector multiples. What is not modeled is the variability across eight implementation parameters — phasing schedule, country carve-outs, reshoring credit mechanism, definition of "final product," generics scope, transfer pricing flexibility, patient access exceptions, and bilateral negotiation outcomes — each of which independently moves the effective tariff rate experienced by individual companies by 20–60 percentage points. The implementation framework is expected to be announced Q2–Q3 2026, creating a discrete event window in which directional positioning becomes possible. This L3 brief is structured around the implementation variables because that is where the analytical work needs to happen: understanding which variables matter most, which scenarios are plausible, and how each company is differentially exposed under each scenario.

Signal vital signs

Headline rate100%

Effective rate range25-100%

Maturity stageImminent

VelocityAccel.

Impl. windowQ2-Q3 '26

Impl. variables8

Modal scenario p~55%

Hard scenario p~20%

Soft scenario p~25%

Channel(s)2 + 6

Implementation variable matrix · eight parameters that determine actual firm-level impact L3 centerpiece

The Section 232 100% headline rate is a maximum theoretical value. The effective rate experienced by any individual firm depends on eight implementation variables that are still being negotiated within the executive branch and with foreign trade partners. The framework's claim is that the spread between hard, modal, and soft scenarios on these variables is wider than implied by current sector volatility — meaning options markets are under-pricing the dispersion of outcomes. The matrix below lays out the eight variables and the working baseline for each under three scenarios. Probabilities are subjective; the goal is not precision but to make the implicit assumptions in any sell-side model visible and contestable.

Implementation variable	Hard implementation~20%	Modal · negotiated~55%	Soft · phased / partial regression~25%
1. Effective tariff rateAfter carve-outs and exceptions, what does the average importer actually pay?	~95%Headline 100% with minimal exceptions. Average importer faces near-full rate on landed value of finished pharmaceutical products.	~55-65%100% on covered products but extensive carve-outs and reshoring credits bring blended rate to roughly 60% for the average importer; bilateral deals for UK and Switzerland reduce specific country rates.	~25-40%SCOTUS challenge on commerce clause grounds (similar to IEEPA) succeeds partially or implementation is stayed pending review; surviving rate is 25-40% on a narrower scope.
2. Phasing scheduleImmediate vs. phased introduction over months or years	ImmediateEffective Q3 2026 with no phase-in. Forces immediate cost absorption or pass-through on existing inventory.	12-18 month phaseTariff begins at 25% in Q3 2026 and steps up by 25% every 4-6 months to reach 100% by end-2027. Allows companies to begin reshoring before full rate hits.	24+ months or stagedFull implementation deferred to 2028+ pending bilateral negotiations and reshoring credit qualification window. May never reach 100% in practice.
3. Country carve-outsBilateral exemptions for specific trading partners	NoneNo bilateral exceptions. Switzerland, UK, Ireland all face full rate.	UK + Switzerland + SingaporeBilateral reciprocal-treatment deals with three jurisdictions. Ireland retains some exposure as part of EU bloc; bilateral EU deal possible but not in baseline.	UK + CH + Sing + Ireland + JapanWider bilateral framework including Ireland (via EU deal), Japan, possibly Canada. Effective tariff scope shrinks to perhaps half of current import volume.
4. Reshoring credit mechanismCapital expenditure offset against tariff liability	NoneNo mechanism for offsetting tariff payments against US capital expenditure commitments. Companies pay full tariff regardless of reshoring intent.	Limited12-month qualifying period for US capex commitments to offset tariff liability up to the committed capex amount. Requires Treasury certification of qualifying projects.	Generous24-36 month qualifying period with broad definition of qualifying capex (including biologics fill-finish, API, packaging). De facto delays the effective tariff for any company willing to commit to US expansion.
5. Definition of "final product"Where in the value chain the tariff bites	Includes packagingTariff applies to packaged finished doses imported in commercial form. US relabeling/repackaging does not avoid the tariff.	Final dose formTariff applies to imported finished dose forms. US fill-finish operations on imported bulk active substance escape the tariff. Creates immediate arbitrage opportunity for US fill-finish capacity.	Branded final dose onlyTariff applies only to fully packaged branded products in commercial form. Bulk imports, intermediate-stage products, and contract manufacturing all carved out.
6. Generics & biosimilars scopeWhether off-patent products are covered	IncludedGenerics and biosimilars fully covered. Creates risk to US generics supply (large share imported from India) and to biosimilar pricing economics.	Generics carved outGenerics excluded explicitly to protect US drug affordability. Biosimilars included but with patient-access exceptions.	Generics + biosimilars carvedBoth excluded. Tariff scope becomes "branded patented small-molecule and biologic finished products" which is a meaningfully narrower base.
7. Transfer pricing flexibilityWhether internal transfer prices can be adjusted to reduce tariff base	No adjustmentTariff calculated on declared customs value with no adjustment mechanism. Forces companies to absorb the rate at full transfer price.	OECD-compliant adjustmentsCompanies can adjust intercompany transfer pricing within OECD arm's-length range, which provides 10-25% effective rate reduction depending on specific value chain.	Section 482 flexibilityIRS Section 482 advance pricing agreements can be used for tariff calculations, providing significant flexibility for companies with sophisticated tax structures.
8. Patient access exceptionsCarve-outs for specific drug classes on access grounds	NoneNo drug-class exceptions. All branded patented products covered including oncology, vaccines, rare disease.	Tropical / rare diseaseLimited exceptions for tropical disease, ultra-rare disease, and pediatric formulations. Most therapeutic areas remain covered.	Plus oncology & vaccinesWider exceptions including all oncology drugs and vaccines. Significantly narrows scope and creates immediate winners among oncology-focused companies.

How to read this table: the eight rows are independent variables, so the effective firm-level rate is the product of the row outcomes rather than a single column read. The "modal" column is not a self-contained scenario but rather the most-likely outcome on each variable considered independently; an actual implementation could combine modal outcomes on some variables with hard or soft outcomes on others. The framework's central claim is that even modest movement on any two of these variables creates dispersion across firms larger than the entire current sector valuation gap. Variables 4 (reshoring credit), 5 (definition of "final product"), and 7 (transfer pricing) are the highest-leverage parameters because they affect the effective tariff rate without changing the headline number, and they are the variables where executive-branch discretion is widest.

Transmission chain · from policy action to corporate P&L

The transmission chain traces how the Section 232 tariff propagates from the policy action (left) through firm response options (middle) to P&L outcomes (right). Each firm response option has a different time profile and a different financial cost, which is why the same headline tariff produces very different gross margin and capex outcomes across companies. The framework's claim is that the response-option choice is determined by the firm-attribute matrix from L2 (manufacturing footprint, modality, balance sheet flexibility) and is largely predictable from current disclosures, which is what makes pre-positioning possible.

Response option attribution: Option A (absorb) is the default for any company with no spare US capacity and no near-term capex flexibility. Option B (pass through) is heavily constrained for any drug under IRA negotiation, in Medicaid via MDRP best-price rules, or with outstanding 340B obligations — meaning it is functionally unavailable for the most exposed product portfolios. Option C (reshore) is the only structural fix but takes 24-48 months from announcement to qualified production and requires $2-15 billion of capex per major facility; only companies with strong balance sheets can pursue this at scale. Option D (transfer pricing) is available only to companies with sophisticated international tax structures and is bounded by OECD arm's-length requirements. Option E (bilateral arbitrage) depends entirely on whether and which carve-outs emerge in the implementation framework. The crucial insight: most companies can only execute one or two of these five options, which creates the firm-level dispersion that L2 identified.

Porter decomposition · how Section 232 alone shifts the five forces

↔ Force 1 of 5

Buyer power

Roughly unchanged from this signal alone. CMS, PBMs, and 340B entities are already dominant buyers and Section 232 doesn't directly change their leverage. The interaction effect is that buyers may resist tariff pass-through more aggressively than absent the tariff because the price increase is visible and politically charged.

Note: large interaction with IRA, PBM signals

↑ Force 2 of 5

Supplier power

Significantly increasing. US-based contract manufacturers (CDMOs, fill-finish) gain pricing power as reshoring demand surges. CDMO capacity is the binding constraint on Option C reshoring, and CDMO multi-year contracts are already being repriced upward in anticipation. Specialty equipment makers and biologics fill-finish equipment manufacturers also gain supplier-side leverage.

Beneficiaries: CDMO, equipment, US-based services

↑ Force 3 of 5

Threat of new entrants

Barriers increase materially. The tariff effectively raises the cost of building a US pharma business from scratch by requiring US final-product manufacturing as a precondition for competitive participation. Foreign companies seeking US market entry now need to commit significant capex up front, which favors well-capitalized incumbents.

Locks in incumbent advantage materially

↔ Force 4 of 5

Substitute threat

Roughly unchanged from this signal alone. Section 232 doesn't directly affect biosimilar or generic substitution dynamics, though the interaction with the generics scope variable matters — if generics are included, substitutes become relatively more expensive too, so substitution dynamics are dampened slightly.

Depends on variable 6 (generics scope)

↑ Force 5 of 5

Internal rivalry

Significantly increasing on differentiated firm exposure. Companies with US manufacturing footprints gain a structural cost advantage over foreign-mfg peers; this is the cleanest example in the entire framework of policy creating new competitive axes. Within US-mfg firms, competition shifts from cost to scale of US capacity; among foreign-mfg firms, competition shifts to who can reshore fastest.

LLY/GILD/VRTX gain at NVS/AZN/JNJ expense

Three scenarios · weighted probability and detailed mechanism

Hard implementation

~20%

Severe / fast

Section 232 implemented near-headline, fast, with minimal carve-outs and no reshoring credit mechanism. Effective average rate ~95%, immediate Q3 2026 effective date, no country bilaterals beyond what is already announced. Generics included; transfer pricing locked at declared customs value; no patient-access exceptions beyond ultra-rare disease.

What it would take: A signal from the White House that the negotiated approach is too slow, possibly triggered by a high-profile drug shortage or a perceived foreign-policy provocation from a major pharma exporter country (most plausibly EU pushback on a different trade matter). The hard scenario requires the executive to override Treasury and USTR's institutional preference for negotiated outcomes.

P&L impact (sector level)

Gross margin: -1200 to -1500 bps for high-exposure firms; -200 bps for low-exposure firms. Sector multiple compression to ~10-11x forward. Capex acceleration of ~$50-80B sector-wide over 24 months. Earnings reset 15-25% lower for the modal large-cap pharma. Pair-trade dispersion widens to 8+ multiple turns.

Soft / phased

~25%

Stayed / partial regression

SCOTUS challenge on commerce clause grounds (similar to the IEEPA regression) succeeds partially, OR implementation is extensively delayed via bilateral negotiations that effectively push the meaningful tariff into 2028+, OR the reshoring credit mechanism is so generous that most major pharma can effectively defer the tariff indefinitely by committing to incremental US capex. Effective average rate is 25-40% on a much narrower scope.

What it would take: The IEEPA SCOTUS case as precedent meaningfully constrains how aggressively Section 232 can be applied to a sector that hasn't traditionally been treated as a national-security priority. Pharma's national security argument is weaker than steel's, which creates legal vulnerability. Alternatively, a rapid succession of bilateral deals could effectively dilute the tariff to a small set of countries.

P&L impact (sector level)

Gross margin: -100 to -200 bps for high-exposure firms; negligible for low-exposure firms. Sector multiple expansion back to 14-15x forward as uncertainty resolves favorably. Capex commitments largely deferred or repurposed. Earnings flat to slightly positive across the sector. Pair-trade dispersion narrows back toward 2-3 multiple turns — relative winners give back some of their relative outperformance.

Per-firm sensitivity grid · gross margin impact under each scenario illustrative

Per-firm gross margin impact under each of the three scenarios. These are illustrative bps estimates derived from each company's L2 firm-attribute exposure — specifically the US manufacturing footprint percentage, the channel-mix constraint on tariff pass-through, and the company's balance sheet flexibility for reshoring response. The point is not the precise numbers but the dispersion pattern across firms within each scenario column. The dispersion under the modal scenario is wide enough to drive the relative-winner trade even before any of the more extreme scenarios materialize.

Company	Hard~20%	Modal~55%	Soft~25%	Exposure driver
LLYEli Lilly	-50	~0	~0	~85% US mfg; minimal foreign final-product exposure. Reshoring optionality already in execution.
GILDGilead	-100	~0	~0	~80% US mfg; HIV antiviral production largely domestic. Modest fill-finish dependency on Ireland.
VRTXVertex	-150	-25	~0	~85% US mfg; rare disease scope may qualify for patient-access exceptions; small foreign exposure.
AMGNAmgen	-300	-75	~0	~70% US mfg; biologic process complexity makes reshoring slower but Amgen has spare US capacity.
REGNRegeneron	-200	-50	~0	~80% US mfg (Tarrytown + Rensselaer); Eylea mostly US-produced; minimal foreign exposure.
MRKMerck	-450	-150	-25	~65% US mfg; Keytruda fill-finish split US/Ireland; reshoring announced but not complete.
PFEPfizer	-800	-300	-50	~50% US mfg; significant Ireland and Belgium exposure; sophisticated transfer pricing structure provides some Option D flexibility.
BMYBristol Myers	-700	-250	-50	~55% US mfg; Eliquis split with Pfizer; Opdivo US-produced; mixed foreign exposure on legacy products.
ABBVAbbVie	-650	-200	-25	~60% US mfg; Puerto Rico exposure has ambiguous Section 232 treatment (US territory); Humira biosimilar already factored.
JNJJohnson & Johnson	-900	-400	-100	~50% US mfg with significant Belgium and Switzerland exposure; Stelara biosimilar already eroding; multi-channel exposure compounds.
AZNAstraZeneca	-1300	-550	-150	~25% US mfg; UK + Sweden + Ireland; UK bilateral carve-out is the swing factor — AZN benefits disproportionately if UK deal happens.
NVSNovartis	-1500	-700	-200	~20% US mfg; Switzerland-dominant; Switzerland bilateral carve-out is the swing factor — NVS benefits disproportionately if Switzerland deal happens.

Reading the grid: the dispersion within the modal column is the most important pattern — it ranges from ~0 bps (LLY/GILD/VRTX) to -700 bps (NVS) on a base sector gross margin of roughly 7500 bps. That spread of 700 bps gross margin difference, applied to ~30% net margin and 12-15x multiples, generates the 5-6 multiple-turn pair-trade dispersion that the framework predicts. The bilateral swing factors (UK deal moving AZN, Switzerland deal moving NVS) are the highest-leverage individual outcomes within the modal scenario and should be tracked closely as separate signposts. Limits: these estimates are first-order pre-mitigation impacts. Companies will execute response options A through E to varying degrees and the realized impacts will be lower than these gross figures, but the relative ordering across firms is robust to mitigation because the underlying constraint (manufacturing footprint) cannot be changed quickly.

Trade expressions · positioning around the implementation announcement probability-weighted

Long LLY / Short NVS

Pair trade · modal-scenario carry

The cleanest framework expression of the relative-winner / compression-case spread. LLY has ~85% US manufacturing and zero IRA Round 1 exposure; NVS has ~20% US manufacturing (Switzerland-dominant) and one Round 1 hit (Entresto). Even in the modal scenario the gross margin spread is roughly 700 bps in LLY's favor, and the spread widens to 1450 bps in the hard scenario. The Switzerland bilateral carve-out is the only thing that materially undermines the trade, and even then NVS still faces fiscal-channel exposure that LLY avoids.

Horizon6-12 months

Sizing$ neutral, beta-adjusted

Risk · CH bilateral~30% of premium

Convexity+ in hard, - in soft

Long GILD / Short AZN

Pair trade · cross-channel diversification

The complementary pair to LLY/NVS. GILD has US manufacturing concentration plus the institutional advantage of low Part D exposure; AZN has the framework's most multi-channel exposure (Trade + Sanctions + Fiscal all active simultaneously). The trade benefits from the same Section 232 mechanism as LLY/NVS but is uncorrelated because the underlying companies operate in different therapeutic areas and would not move together on idiosyncratic news. The UK bilateral carve-out is the swing factor; even with a UK deal, AZN's China operations create independent sanctions-channel exposure that GILD doesn't share.

Horizon6-12 months

Sizing$ neutral, beta-adjusted

Risk · UK bilateral~25% of premium

Diversifiesw/ LLY/NVS pair

Long XPH put spread · Q3 expiry

Directional · hard scenario hedge

Buy XPH (S&P Pharmaceuticals SPDR) put spreads dated to Q3 2026 expiry, struck around -10% and -25% from spot. Designed to capture the hard-scenario tail (~20% probability) without paying full directional carry against the modal scenario. The asymmetry is favorable because hard-scenario implied vol is currently priced as roughly average rather than as a discrete event premium, and put-spread structure caps the carry cost while preserving most of the tail upside. Best executed in size after the implementation framework is announced if the framework reads closer to hard than modal.

Horizon3-6 months

Cost~1.5% of notional

Max payoff~10x cost

Triggerframework leak/announcement

CDMO basket long

Beneficiary · supplier-power play

The Porter decomposition identifies US-based contract manufacturers as the cleanest beneficiary of any Section 232 implementation that includes a meaningful reshoring response. Catalent (now Novo Holdings), Lonza, Thermo Fisher (Patheon), and Wuxi STA are the major listed CDMO platforms; the framework call is to be long the US-capacity-heavy names and short the China-capacity-heavy names (Wuxi STA in particular faces BIOSECURE exposure that compounds with the Section 232 demand). This trade works under all three scenarios because reshoring optionality is being purchased even if it isn't ultimately exercised at full intensity.

Horizon12-18 months

Sizingbasket, equal weight

Works inall 3 scenarios

Cross-thesisalso long BIOSECURE

Signposts · what to watch for scenario resolution

Apr-May '26

Section 232 working group leaks on implementation framework structure. Treasury & USTR readouts and industry trade group statements are the early warning channel. Hard signals: White House override of working group recommendations.

May-Jun '26

UK and Switzerland bilateral negotiation status — both jurisdictions are actively engaged. Status updates from UK Department for Business & Trade and from Swiss FDFA give early read on whether bilateral carve-outs are on track.

Q2 '26

Implementation framework formal announcement — the discrete event around which positioning needs to be adjusted. The announcement will resolve most of the eight implementation variables in one document.

Q2-Q3 '26

Pharma industry reshoring announcements — LLY (Indianapolis expansion), MRK (Durham), PFE (multiple sites) have already announced; watch for second-wave announcements from JNJ, BMY, and especially ABBV (which has the most flexibility via Puerto Rico).

Q3 '26

SCOTUS docket updates on potential Section 232 challenges — pharma trade groups and individual companies have telegraphed willingness to challenge on commerce-clause grounds. Cert grant on any related petition is the soft-scenario trigger.

Q4 '26

Earnings calls Q3 2026 — first reporting period after framework announcement. Management commentary on capex commitments, pricing strategy, and Section 232 net impact will drive the next round of analyst estimate revisions. Consensus typically lags reality by 2 quarters on signal of this magnitude.

L3 Section 232 100% pharma tariff · April 8 2026. First L3 deep-dive built using the v2 six-channel taxonomy. The signal carries Trade & market access as primary channel and Institutional & political risk as secondary — the secondary tag matters because the implementation discretion is wide enough that executive-branch posture and SCOTUS reviewability are real factors in scenario probabilities.

What this build tests about the framework. The L3 architecture's claim is that per-signal deep dives produce specific, testable trade expressions that institutional investors can act on directly, and that they do so by making the implementation-detail variability the analytical centerpiece rather than relying on the headline policy. This build executes that pattern. The implementation variable matrix is structured so that any user (investor or corporate) can inspect their own model assumptions about each variable, see where they differ from the framework's working baselines, and locate the resulting impact on their specific exposure. The transmission chain shows how response options A through E are differentially available to companies based on their attribute matrix from L2; the firm impact grid translates that into bps gross margin sensitivities; the trade expressions section converts the analysis into actionable positioning.

What this build flags about the framework. (1) The "implementation variables as analytical centerpiece" approach is unusually appropriate for Section 232 because so much of the impact depends on executive discretion. For other signals (IRA Part D selection, FTC enforcement) the centerpiece may be different — we should not assume every L3 has eight variables to track. (2) The probability weights on the three scenarios are explicit subjective judgments rather than derived from any prediction-market or model output; the framework's value is in making them visible and contestable, not in claiming precision. (3) The firm impact grid is the most directly stress-testable element because it produces numbers that can be compared to realized outcomes; this should be revisited and graded after the implementation framework announcement.

Dual audience note. This build is investor-primary in framing — the synthesis layer is "trade expressions" rather than "decision frameworks." For corporate users, the analytical layer (implementation variable matrix, transmission chain, scenario grid, firm impact sensitivities) translates directly: a corporate strategy team can use the same eight variables as a checklist for their own contingency planning, can use the response option taxonomy (A absorb / B pass-through / C reshore / D transfer pricing / E bilateral arbitrage) as a framework for evaluating their own optionality, and can use the firm impact grid as a benchmark against which to position their own gross margin sensitivity modeling. A future build could add an explicit "corporate decision framework" section parallel to "trade expressions" if there is appetite for it; for now, the structural design is intended to serve both audiences without compromising either.

Methodology & limits. All scenario probabilities, implementation variable assumptions, firm exposure scores, and bps impact estimates are analyst judgment rather than quantitative model output. The "modal" scenario reflects the working baseline as of April 8 2026 and will need to be re-versioned as the implementation framework approaches. Reading the document at a future date should start with the date stamp because the underlying signal landscape is moving fast.

Next steps. Build (a) L3 for IRA Part D Round 2 selection ahead of February 2027 announcement, and (b) L3 for FTC patent thicket enforcement on Stelara, as the next two highest-velocity signals affecting pharma. Apply the implementation-variable-matrix L3 pattern to test whether it generalizes to other Section 232 actions (steel restructure, semis chips deferred). And re-version this document after the implementation framework is announced — the post-event re-version is the clearest test of whether the framework's pre-event positioning would have been correct.